Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus TRICHLORMAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus TRICHLORMAS.
ENDURONYL FORTE vs TRICHLORMAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
TRICHLORMAS is a sedative-hypnotic agent. Its mechanism of action is not fully understood but is believed to involve potentiation of GABAergic inhibition in the central nervous system, similar to other chloral derivatives. It is metabolized to trichloroethanol, which is the active hypnotic compound.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
500 mg orally once daily at bedtime, increased as needed to a maximum of 1 g per day in divided doses; for insomnia, 1-2 g orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Terminal elimination half-life is approximately 8-11 hours for the parent drug in adults with normal renal function. In patients with hepatic impairment, half-life may be prolonged up to 30 hours; in severe renal impairment, half-life of metabolites may increase significantly.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Primarily renal via glomerular filtration and tubular secretion; about 70-80% of the dose excreted unchanged in urine within 24 hours. The remainder is metabolized to trichloroethanol (active) and trichloroacetic acid; these metabolites are also eliminated renally.
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic